Miracle-dz/UniFAR-FTUs huggingface dataset:
Cardiac hepatopathy: Clinical, hemodynamic, and histologic characteristics and correlations

Cardiac hepatopathy, hepatic injury caused by cardiac dysfunction, is a common entity but has been characterized incompletely, particularly the relationship between hemodynamics and histology. We aimed to describe the clinical, biochemical, hemodynamic, and histologic characteristics of this disorder. Eighty‐three patients from 2 tertiary referral centers were studied. Patients were divided into 3 groups based on the duration of cardiac dysfunction: (1) acute (n = 12); (2) chronic (n = 53); and (3) acute on chronic (n = 18). Results showed that serum aminotransferase levels were increased typically, particularly in the acute group (median aspartate aminotransferase level was 30.2 times the upper limit of normal [range, 1‐100]; P < .0001 vs. the chronic group). The most salient hemodynamic features were elevated right atrial (14 mm Hg [range, 1‐29]), and hepatic venous pressures (wedged: 18 mm Hg [range, 5‐35]; free: 15 mm Hg [range, 2‐30]). The hepatic venous pressure gradient was normal in most (81%), correlated moderately with the aminotransferase levels (aspartate aminotransferase level: r = .59; P < .0001), and associated with the presence of centrilobular necrosis and inflammation, periportal necrosis, and stainable hepatic iron (P < .05 for all comparisons), but not fibrosis. Sinusoidal dilatation was associated with higher right atrial (P = .047) and free hepatic venous pressures (P = .06). Although cirrhosis was rare (n = 1), centrilobular fibrosis was common (74%) and not associated with any hemodynamic measurement. In conclusion, cardiac hepatopathy has diverse clinical, hemodynamic, and histologic manifestations that vary with the temporal course of cardiac dysfunction. Hepatic fibrosis is common, but does not correlate with systemic or hepatic hemodynamics.
Comparison of Six Commercial Techniques in the Measurement of Microalbuminuria in Diabetic Patients

OBJECTIVE To evaluate the advantages and drawbacks of six commercially available techniques in the measurement of microalbuminuria in diabetic patients. RESEARCH DESIGN AND METHODS Timed overnight urine samples from 75 patients in our diabetic clinic were tested with 2 qualitative tests (Micral-Test and Microbumintest) and assayed with 4 quantitative tests, which used different methodologies: double-antibody RIA, RID, IT, and NEPH. All tests were commercially available. The double-antibody RIA was taken as the golden standard. All urine samples were either negative or trace by Albustix (Ames, Elkhart, IN). Interobserver variation for the 2 qualitative tests was assessed by asking 12 experienced nurses to read the color changes on the dipsticks and the tablets simultaneously, using test solutions with albumin concentrations of 16, 32, and 64 mg/L. RESULTS The 75 urine samples contained 0–154.2 mg/L of albumin. Correlation coefficients of RID, NEPH, and IT with RIA were 0.970, 0.975, and 0.974, respectively. Intra-assay and interassay CVs ranged from 1.36–11.5%. Microbumintest had a higher sensitivity (100 vs. 75%), but lower specificity (82.5 vs. 87.3%) than Micral-Test. Considerable interobserver variation existed in the matching of colors for both tests. Discrepancies were especially significant with Microbumintest, with 8 of 12 nurses misreading the 32 mg/L level. CONCLUSIONS Correlations of the 3 quantitative methods with RIA were all >0.970. Choice of test may depend more on considerations such as time, space, number of specimens to be handled, and availability of instruments. Both qualitative tests showed a relatively low specificity. Positive tests must be confirmed with quantitative assays before microalbuminuria is diagnosed. Microbumintest had a higher sensitivity, but its unacceptably high interobserver variation and lower specificity were serious drawbacks.
Differences in neonatal and postneonatal mortality by race, birth weight, and gestational age.

In recent decades, neonatal and postneonatal mortality rates have declined overall in the United States. Yet, the mortality rates for black infants continue to be approximately twice those for white infants. With the use of data from 45 of the 53 vital statistics reporting areas that participated in the 1980 National Infant Mortality Surveillance project, we extended previous State analyses to describe differences, nationally, in neonatal and postneonatal mortality risks for black and white infants according to gestational age and birth weight. After restricting our analysis to single-delivery infants with known and plausible combinations of gestational age of 26 or more weeks and birth weights of 500 grams (g) or more, the neonatal mortality risk (NMR)--that is, the number of deaths to infants less than 28 days of life per 1,000 live births--for black infants was 1.6 times higher than the NMR for whites. This difference was largely explained by two findings: First, although the NMR was lower for black than for white infants with gestational ages of less than 38 weeks and birth weights less than 3,000 g, that advantage was heavily outweighed by the higher percentage of such births among blacks, accounting for roughly two-thirds of the overall difference in NMR between blacks and whites. Second, most of the remaining difference in NMR was accounted for by higher NMRs among black infants with gestational ages of 38 or more weeks and birth weights of 3,000 g or more. A comparison of the lowest mortality risk for any combination of birth weight and gestational age showed that the black NMR was 1.89 times higher than the white NMR. The postneonatal mortality risk (PNMR)--PNMR equals the number of deaths to infants 28 days to less than 1 year of life per 1,000 neonatal survivors--for black infants was 2.09 times the PNMR for white infants. Black infants had higher PNMRs than white infants for nearly all combinations of birth weight and gestational age. Higher PNMRs among infants with gestational ages of 38 or more weeks and birth weights of 2,500 g or more accounted for 43 percent of the difference in PNMR between black infants and white infants. Eliminating the U.S. black-white infant mortality disparity will require not only reducing the higher frequency of prematurity and low birth weight among black infants, but also improving the survival during both the neonatal and postneonatal periods of term black infants with normal birth weights.
Gait in patients with cerebellar ataxia

The gait pattern in 10 patients with cerebellar degenerations was studied and the results were compared with 10 matched normal subjects, seeking the principal patterns in this disorder. Gait at natural speed was studied in a biomechanics laboratory using a video‐based kinematic data acquisition system for measuring body movements. Patients showed a reduced step and stride length with a trend to reduced cadence. Heel off time, toe off time, and time of peak flexion of the knee in swing were all delayed. Range of motion of ankle, knee, and hip were all reduced, but only ankle range of motion reached significance. Multijoint coordination was impaired, as indicated by a relatively greater delay of plantar flexion of the ankle compared with flexion of the knee and a relatively late knee flexion compared with hip flexion at the onset of swing. The patients also showed increased variability of almost all measures. Although some of the deviations from normal were simply the result of slowness of walking, the gait pattern of patients with cerebellar degeneration shows incoordination similar to that previously described for their multijoint limb motion.
Exploring social policy ideas and language

The literature on the role of ideas in public and social policy has expanded dramatically over the last two decades (Hall 1993; Merrien 1997; Stone 2001; Blyth 2002; Parsons 2007; Campbell 2004; Orenstein 2008; Padamsee 2009; Jenson 2010; Mehta 2011; Béland and Cox 2011; Schmidt 2011; Béland 2016a). The objective of this chapter is to map different types of ideas and the actors carrying them in order to show how ideas can play a direct role in social policy change, at both the national and the transnational level, in Europe and beyond. The first part of the chapter defines ‘ideas’ and their various types before answering two related questions about the potential impact of ideas on social policy change: where do policy ideas come from; and how, and through which actors, are global ideas diffused and adapted to national context? As suggested, studying the role of ideas requires an analysis of the different forms they can take, the diversity of actors carrying them, and the diffusion and translation processes through which ideas move back and forth between the national and the transnational level. The second part of the chapter focuses on a less-studied issue directly related to the role of ideas: how social policy language and key concepts such as ‘welfare state’ and ‘social security’ emerge and diffuse over time, at both the national and the transnational level. As suggested, the analysis of social policy language and concepts offers a new research agenda about the relationship between ideas and social policy development.
In Vivo Stimulation of Vascular Plasminogen Activator Inhibitor-1 Production by very Low-Density Lipoprotein Involves Transcription Factor Binding to a VLDL-Responsive Element

Summary High plasma levels of plasminogen activator inhibitor-1 (PAI-1) are associated with an increased risk of cardiovascular disease. There is also a close relation between high plasma levels of PAI-1 and hypertriglyceridemia. Cell culture studies have shown that very low density lipoprotein (VLDL) increases the production and secretion of PAI-1 in endothelial cells and hepatocytes, suggesting a possible mechanism for this association. To determine whether VLDL stimulates PAI-1 production in vascular cells also in vivo, Sprague-Dawley rats were injected intravenously with 6 mg/kg of VLDL (derived from human subjects with type IV hyperlipidemia). Previous studies have demonstrated that this results in an accumulation of human VLDL in the aorta and other arteries followed by increased nuclear factor-kappa B (NF-κB) activation. Endothelial, but not smooth muscle cells, showed a basal PAI-1 mRNA and protein expression as assessed by in situ hybridization and immunohistochemistry, respectively. Six to twenty-four hours after the VLDL injection, lipoprotein particle accumulation was seen in the aortic wall, which was accompanied by increasing PAI-1 mRNA and protein expression in endothelial and smooth muscle cells. Within the rat PAI-1 promoter we identified a sequence located at −589 to −571 with 74% homology with the recently described VLDL responsive element in the human PAI-1 promoter and located adjacent to a 4-guanosine motif presumably corresponding to the human 4G/5G polymorphism. Transient transfection studies showed that VLDL exerts its stimulatory effects on rat PAI-1 gene expression in vascular cells by interaction with promoter sequences located within bp −656 and −505. Electrophoretic mobility shift assays showed that VLDL increases the binding of as yet incompletely characterized factors to this response element. Taken together these observations support a direct influence of VLDL on vascular PAI-1 gene expression in vivo. This stimulation is exerted on the level of PAI-1 gene transcription, and involves transcription factor binding to a VLDL responsive element adjacent to a 4G motif within the PAI-1 promoter.
Impact of Middle East emerging carriers on US and EU legacy airlines

Airlines in the Middle East have captured significant attention from governments, media and consumers over the past decade. By building large networks that facilitate international connections at their hubs, Middle East carriers are able to compete in a wide range of origin destination markets around the globe. Three of these carriers stand out with their recent expansion to European, US and Asian destinations: Emirates, Etihad Airways and Qatar Airways, also known as the ME3 carriers. From a capacity perspective, ME3 airlines have grown very rapidly on routes where they compete with US and European airlines. Over the 2010-2015 period, from Europe to the ME, ME3 airlines increased their seat capacity by 97% against a 1% reduction by European legacy carriers. At the same time, ME3 carriers increased the number of seats from the US by 181% while, as of 2017, US carriers have cut all flights to the Middle East, with the exception of Israel. In addition, ME3 capacity to Asia, and in particular to India, grew significantly. From a traffic perspective, ME3 carriers have had a significant impact in markets beyond the Middle East. Passenger traffic in the EU-India and US-India markets grew by 14% and 26% respectively since 2010. Most of the growth was driven by ME3 carriers, allowing them to reach 26% and 37% market share in these markets in 2015. The ME3 capacity growth likely stimulated the overall demand in markets to India but has also caused some diversion of traffic away from nonME3 carriers. In a two-way fixed effect econometric model, we estimated that the presence of ME3 carriers in average EU-India and US-India markets diverted, respectively, 20% and 32% of nonME3 traffic to ME3 carriers. The growing influence of ME3 carriers has led to significant controversy over claims of subsidies and unfair competition from both US and ME3 airlines. Based on a brief review of the various claims, we found that both sides have received government backing. It is difficult to determine whether either of the parties have violated established competition rules while benefiting from this support. Nonetheless, the dispute is likely to continue, if not for legal purposes at least for public relations and political purposes. Thesis Supervisor: Peter P. Belobaba Title: Principal Research Scientist of Aeronautics and Astronautics
Development of multi-type secondary-battery charger/discharger by arbitrary current waveform

A cost effective circuit to charge and discharge secondary batteries by an arbitrary current waveform is developed for investigating deterioration characteristics of the batteries. A charging management integrated circuit (IC) is employed for controlling both charging and discharging because there are few ICs to control the discharging of the batteries. The circuit configuration with the common ICs reduces the cost of the test system. This system can easily deteriorate the secondary batteries by a computer controlled current waveform. The developed circuit enables to charge/discharge different kinds of batteries such as series-connected lithium-ion (Li-ion), nickel metal hydride (Ni-MH) and lead acid (Pb) batteries with nominal voltages from 2 to 9 V.
A meta-analysis: The diagnostic values of long non-coding RNA as a biomarker for gastric cancer

Long non-coding RNAs (lncRNAs) have been identified as novel biomarkers for the diagnosis, staging and prognosis for gastric cancer. However, various studies have reported a series of significances based on different diagnostic values. Therefore, the current study performed a systematic review and meta-analysis to evaluate the diagnostic accuracy of lncRNAs for gastric cancer, and to discuss lncRNA types and sources of heterogeneity. The Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, EMBASE, the Chinese Biomedical Literature Database, the China Academic Journals Full-text Database and the Chinese Scientific Journals Database were systematically searched for potential studies. Studies were included if they were associated with lncRNAs, gastric cancer and reported diagnostic outcomes. Analysis of diagnostic values was used to summarize the overall test performance of lncRNAs. Ten studies were included in this meta-analysis. The ranges of the diagnostic value of lncRNAs for gastric cancer were as follows: Sensitivity was 0.45–0.83, and pooled sensitivity was 0.63; specificity was 0.60–0.93, and pooled specificity was 0.75; positive likelihood ratio was 1.80–6.92, and pooled positive likelihood ratio was 2.51; negative likelihood ratio was 0.23–0.67, and pooled negative likelihood ratio was 0.50; diagnostic odds ratio was 3.33–13.75, and pooled diagnostic odds ratio was 5.47. An overall area under the curve value of the summary receiver operating characteristic curve was 0.7550. LncRNAs did not have a high accuracy for identifying gastric cancer at present, but may be a useful screening tool for diagnosing gastric cancer due to their correlation with gastric cancer biological features. LncRNAs are potential biomarkers for gastric cancer if the screening strategy is altered, or they are combined with other biomarkers to diagnose gastric cancer.
Comorbidity of chronic insomnia with medical problems.

STUDY OBJECTIVES Determine the comorbidity of insomnia with medical problems. DESIGN Cross-sectional and retrospective. PARTICIPANTS Community-based population of 772 men and women, aged 20 to 98 years old. MEASUREMENTS Self-report measures of sleep, health, depression, and anxiety. RESULTS People with chronic insomnia reported more of the following than did people without insomnia: heart disease (21.9% vs 9.5%), high blood pressure (43.1% vs 18.7%), neurologic disease (7.3% vs 1.2%), breathing problems (24.8% vs 5.7%), urinary problems (19.7% vs 9.5%), chronic pain (50.4% vs 18.2%), and gastrointestinal problems (33.6% vs 9.2%). Conversely, people with the following medical problems reported more chronic insomnia than did those without those medical problems: heart disease (44.1% vs 22.8%), cancer (41.4% vs 24.6%), high blood pressure (44.0% vs 19.3%), neurologic disease (66.7% vs 24.3%), breathing problems (59.6% vs 21.4%), urinary problems (41.5% vs 23.3%), chronic pain (48.6% vs 17.2%), and gastrointestinal problems (55.4% vs 20.0%). When all medical problems were considered together, only patients with high blood pressure, breathing problems, urinary problems, chronic pain, and gastrointestinal problems continued to have statistically higher levels of insomnia than those without these medical disorders. CONCLUSION This study demonstrates significant overlap between insomnia and multiple medical problems. Some research has shown it is possible to treat insomnia that is comorbid with select psychiatric (depression) and medical (eg, pain and cancer) disorders, which in turn increases the quality of life and functioning of these patients. The efficacy of treating insomnia in many of the above comorbid disorders has not been tested, indicating a need for future treatment research.
Morphological Study of the Encystment and Excystment of Vermamoeba vermiformis Revealed Original Traits

Free‐living amoebae are ubiquitous protozoa commonly found in water. Among them, Acanthamoeba and Vermamoeba (formerly Hartmannella) are the most represented genera. In case of stress, such as nutrient deprivation or osmotic stress, these amoebae initiate a differentiation process, named encystment. It leads to the cyst form, which is a resistant form enabling amoebae to survive in harsh conditions and resist disinfection treatments. Encystment has been thoroughly described in Acanthamoeba but poorly in Vermamoeba. Our study was aimed to follow the encystment/excystment processes by microscopic observations. We show that encystment is quite rapid, as mature cysts were obtained in 9 h, and that cyst wall is composed of two layers. A video shows that a locomotive form is likely involved in clustering cysts together during encystment. As for Acanthamoeba, autophagy is likely active during this process. Specific vesicles, possibly involved in ribophagy, were observed within the cytoplasm. Remarkably, mitochondria rearranged around the nucleus within the cyst, suggesting high needs in energy. Unlike Acanthamoeba and Naegleria, no ostioles were observed in the cyst wall suggesting that excystment is original. During excystment, large vesicles, likely filled with hydrolases, were found in close proximity to cyst wall and digest it. Trophozoite moves inside its cyst wall before exiting during excystment. In conclusion, Vermamoeba encystment/excystment displays original trends as compare to Acanthamoeba.
An Energy-Efficient, Dynamic Voltage Scaling Neural Stimulator for a Proprioceptive Prosthesis

This paper presents an 8 channel energy-efficient neural stimulator for generating charge-balanced asymmetric pulses. Power consumption is reduced by implementing a fully-integrated DC-DC converter that uses a reconfigurable switched capacitor topology to provide 4 output voltages for Dynamic Voltage Scaling (DVS). DC conversion efficiencies of up to 82% are achieved using integrated capacitances of under 1 nF and the DVS approach offers power savings of up to 50% compared to the front end of a typical current controlled neural stimulator. A novel charge balancing method is implemented which has a low level of accuracy on a single pulse and a much higher accuracy over a series of pulses. The method used is robust to process and component variation and does not require any initial or ongoing calibration. Measured results indicate that the charge imbalance is typically between 0.05%-0.15% of charge injected for a series of pulses. Ex-vivo experiments demonstrate the viability in using this circuit for neural activation. The circuit has been implemented in a commercially-available 0.18 μm HV CMOS technology and occupies a core die area of approximately 2.8 mm2 for an 8 channel implementation.
Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis.

BACKGROUND The majority of liver fibrosis and liver cirrhosis cases in the Western World is caused by alcohol and hepatotoxic viruses. Colchicine is an anti-inflammatory and anti-fibrotic medication. Several randomised clinical trials have addressed the question whether colchicine has any efficacy in patients with alcoholic as well as non-alcoholic fibrosis and cirrhosis. OBJECTIVES The objectives were to assess the efficacy of colchicine on mortality, clinical symptoms and complications, liver biochemistry, liver fibrosis markers, liver histology, alcohol consumption, quality of life, and health economics in patients with alcoholic and non-alcoholic fibrosis or cirrhosis, excluding primary biliary cirrhosis and other rarer forms of fibrosis/cirrhosis. Also adverse events were assessed. SEARCH STRATEGY The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Library, MEDLINE, and full text searches were combined. SELECTION CRITERIA Only randomised clinical trials were included studying patients with alcoholic fibrosis, alcoholic hepatitis and/or alcoholic cirrhosis as well as patients with viral induced or cryptogenic fibrosis and/or cirrhosis according to the diagnostic work-up of the individual trial. Interventions encompassed peroral colchicine at any dose versus placebo or no intervention. The trials could be double-blind, single-blind or unblinded. The trials could be unpublished or published and no language limitations were applied. DATA COLLECTION AND ANALYSIS All analyses were performed according to the intention-to-treat method. The statistical package (RevMan and MetaView) provided by the Cochrane Collaboration was used. The methodological quality of the randomised clinical trials was evaluated by the Jadad-scale. MAIN RESULTS Combining the results of 14 randomised clinical trials including 1150 patients demonstrated no significant effects of colchicine on mortality (Peto odds ratio (OR) 0.90, 95% confidence interval (CI) 0.63 to 1.29), liver related mortality (OR 1.05, 95% CI 0.61 to 1.80), complications (OR 1.01, 95% CI 0.63 to 1.62), liver biochemistry, liver histology, and alcohol consumption (OR 1.02, 95% CI 0.58 to 1.79). Colchicine was associated with a significantly increased risk of adverse events (OR 4.92, 95% CI 2.66 to 9.10; P< 0.001). REVIEWER'S CONCLUSIONS Colchicine should not be used for alcoholic, viral, or cryptogenic liver fibrosis or liver cirrhosis outside randomised trials.